---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-022947"
form_type: "8-K"
ticker: "OPRX"
cik: "0001448431"
company_name: "OptimizeRx Corp"
filed_at: "2025-03-12T23:59:59+00:00"
generated_at: "2026-05-24T22:14:39.463961+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# OptimizeRx Q4 revenue up 14% to $32.3M; FY2025 guidance at least $100M revenue

## Summary
- Q4 revenue $32.3M (+14% YoY); gross profit $22.0M (+23% YoY, margin 68%).
- GAAP net loss $(0.1)M in Q4; full-year GAAP net loss $(20.1)M or $(1.10)/share.
- Non-GAAP net income $5.5M ($0.30 diluted) in Q4; Adj. EBITDA $8.8M (+53% YoY).
- FY2025 guidance: revenue at least $100M, adjusted EBITDA at least $12M.
- Net revenue retention 121% in 2024 vs 105% in 2023; 48 DAAP deals (up from 24).

## SEC filing metadata
- accession: 0001213900-25-022947
- form_type: 8-K
- ticker: OPRX
- cik: 0001448431
- company_name: OptimizeRx Corp
- filed_at: 2025-03-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1448431/000121390025022947/0001213900-25-022947-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1448431/000121390025022947/ea0234059-8k_optimize.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-022947
- JSON: https://secwatch.observer/filing/0001213900-25-022947.json
- Plain text: https://secwatch.observer/filing/0001213900-25-022947.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.